Literature DB >> 24834927

siRNA against KIR3DL1 as a potential gene therapeutic agent in controlling HIV-1 infection.

Geng-Feng Fu1, Ji-Cheng Pan, Nan Lin, Hai-Yang Hu, Wei-Ming Tang, Jin-Shui Xu, Xiao-Liang Wang, Xiao-Qin Xu, Tao Qiu, Xiao-Yan Liu, Guo-Hong Chen, Tanmay Mahapatra, Xi-Ping Huan, Hai-Tao Yang.   

Abstract

OBJECTIVES: The aim of this study was to develop a small interfering RNA (siRNA) against the expression of KIR3DL1 receptor on natural killer (NK) cells, in order to promote the ability of NK cells to destroy human immunodeficiency virus (HIV)-infected cells and thus prevent failure of siRNA therapy targeting human immunodeficiency virus type 1 (HIV-1) virus among HIV-1 infected patients in vitro.
METHODS: A siRNA targeting KIR3DL1 was synthesized and then modified with cholesterol, methylene, and sulfate. The inhibitory action of the siRNAs on primary cultured NK cells was detected. The amount of IFN-γ and TNF-α secretions in NK cells was measured. The intended functions of NK cells in vitro were analyzed by CFSE and PI methods.
RESULTS: There were no significant differences in inhibiting the expression of KIR3DL1 on NK cells between the modified and unmodified siRNAs, while inhibition by each of them differed significantly from controls. The amount of IFN-γ and TNF-α secretions in the NK cells was abundant due to unsuccessful expression of KIR3DL1 on NK cells, which further promoted function of the NK cells.
CONCLUSION: The siRNA against KIR3DL1 could enhance the ability of the NK cells to kill the HIV-1 infected cells in vitro and successfully prevented the failure of siRNA therapy targeting the HIV-1 virus. Therefore, it can act as a potential gene therapeutic agent among HIV-1 infected people.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24834927      PMCID: PMC4043363          DOI: 10.1089/vim.2013.0126

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  28 in total

Review 1.  Current developments in anti-HIV/AIDS gene therapy.

Authors:  Alexander Y Tsygankov
Journal:  Curr Opin Investig Drugs       Date:  2009-02

Review 2.  The challenge of finding a cure for HIV infection.

Authors:  Douglas D Richman; David M Margolis; Martin Delaney; Warner C Greene; Daria Hazuda; Roger J Pomerantz
Journal:  Science       Date:  2009-03-06       Impact factor: 47.728

3.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

4.  Interaction between KIR3DL1 and HLA-B*57 supertype alleles influences the progression of HIV-1 infection in a Zambian population.

Authors:  A López-Vázquez; A Miña-Blanco; J Martínez-Borra; P D Njobvu; B Suárez-Alvarez; M A Blanco-Gelaz; S González; L Rodrigo; C López-Larrea
Journal:  Hum Immunol       Date:  2005-03       Impact factor: 2.850

5.  An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice.

Authors:  Charles Preston Neff; Jiehua Zhou; Leila Remling; Jes Kuruvilla; Jane Zhang; Haitang Li; David D Smith; Piotr Swiderski; John J Rossi; Ramesh Akkina
Journal:  Sci Transl Med       Date:  2011-01-19       Impact factor: 17.956

6.  Low expression of inhibitory natural killer receptors in CD8 cytotoxic T lymphocytes in long-term non-progressor HIV-1-infected patients.

Authors:  Paola Costa; Stefano Rusconi; Manuela Fogli; Domenico Mavilio; Giuseppe Murdaca; Francesco Puppo; Maria Cristina Mingari; Massimo Galli; Lorenzo Moretta; Andrea De Maria
Journal:  AIDS       Date:  2003-01-24       Impact factor: 4.177

7.  A combinatorial library of lipid-like materials for delivery of RNAi therapeutics.

Authors:  Akin Akinc; Andreas Zumbuehl; Michael Goldberg; Elizaveta S Leshchiner; Valentina Busini; Naushad Hossain; Sergio A Bacallado; David N Nguyen; Jason Fuller; Rene Alvarez; Anna Borodovsky; Todd Borland; Rainer Constien; Antonin de Fougerolles; J Robert Dorkin; K Narayanannair Jayaprakash; Muthusamy Jayaraman; Matthias John; Victor Koteliansky; Muthiah Manoharan; Lubomir Nechev; June Qin; Timothy Racie; Denitza Raitcheva; Kallanthottathil G Rajeev; Dinah W Y Sah; Jürgen Soutschek; Ivanka Toudjarska; Hans-Peter Vornlocher; Tracy S Zimmermann; Robert Langer; Daniel G Anderson
Journal:  Nat Biotechnol       Date:  2008-04-27       Impact factor: 54.908

Review 8.  The promises and pitfalls of RNA-interference-based therapeutics.

Authors:  Daniela Castanotto; John J Rossi
Journal:  Nature       Date:  2009-01-22       Impact factor: 49.962

9.  HIV-1 Escape From RNAi Antivirals: Yet Another Houdini Action?

Authors:  Ben Berkhout; Atze T Das
Journal:  Mol Ther Nucleic Acids       Date:  2012-06-12       Impact factor: 10.183

Review 10.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

View more
  2 in total

Review 1.  Cell-penetrating peptides and their analogues as novel nanocarriers for drug delivery.

Authors:  Samira Jafari; Solmaz Maleki Dizaj; Khosro Adibkia
Journal:  Bioimpacts       Date:  2015-04-22

2.  Potential application of injectable chitosan hydrogel treated with siRNA in chronic rhinosinusitis therapy.

Authors:  Cheng Cao; Chunhong Yan; Zhiqiang Hu; Shao Zhou
Journal:  Mol Med Rep       Date:  2015-08-21       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.